Lyra Therapeutics (LYRA)
(Real Time Quote from BATS)
$0.26 USD
0.00 (0.39%)
Updated Oct 2, 2024 11:06 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Lyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 58 | 44 | 22 | 17 |
Income After Depreciation & Amortization | -67 | -56 | -44 | -22 | -17 |
Non-Operating Income | 5 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -63 | -55 | -44 | -22 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -55 | -44 | -22 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -55 | -44 | -22 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -70 | -56 | -43 | -22 | -16 |
Depreciation & Amortization (Cash Flow) | -3 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -67 | -56 | -44 | -22 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.80 | 30.24 | 12.99 | 8.59 | NA |
Diluted EPS Before Non-Recurring Items | -1.23 | -1.83 | -3.35 | -2.59 | NA |
Diluted Net EPS (GAAP) | -1.26 | -1.83 | -3.35 | -2.59 | NA |
Fiscal Year end for Lyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.60 | 0.53 | 0.15 | 0.54 | 0.46 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.60 | 0.53 | 0.15 | 0.54 | 0.46 |
SG&A, R&D, and Dept/Amort Expenses | 49.57 | 24.06 | 16.63 | 17.37 | 16.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | -48.97 | -23.53 | -16.48 | -16.83 | -16.50 |
Non-Operating Income | 0.86 | 1.09 | 1.34 | 1.19 | 0.90 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -48.12 | -22.44 | -15.14 | -15.64 | -15.61 |
Income Taxes | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -48.13 | -22.45 | -15.16 | -15.65 | -15.62 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -48.13 | -22.45 | -15.16 | -15.65 | -15.62 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 65.46 | 64.01 | 67.96 | 56.95 | 43.68 |
Diluted EPS Before Non-Recurring Items | -0.29 | -0.35 | -0.22 | -0.27 | -0.33 |
Diluted Net EPS (GAAP) | -0.74 | -0.35 | -0.19 | -0.27 | -0.36 |